A policy eliminating rebates in the Medicare Part D program will be delayed until Jan. 1, 2026 – and is very likely to be repealed altogether. If that staves off more draconian reforms, the biopharma industry will celebrate.
When the bipartisan infrastructure bill becomes law later this year, the US pharmaceutical industry will have contributed over $50 billion in “savings” to fund the new investments – but most companies won’t in fact feel the loss of a single penny.
Welcome to the world of Congressional Budget Office “scoring,” the official process by which Congress keeps track of how much...
While the government announces eight to 15% cuts to the four products, industry groups urges for its operational improvement without expansion.
Vertex and Biogen are working with the Dutch government to ensure access for eligible patients.
The arrangement, which implies a behind the scenes negotiated discount, may signal a trend toward less price transparency in foreign markets as manufacturers parry Trump’s Most Favored Nation price demands.
The findings are consistent with some other research and likely are due to obesity patients becoming more connected to needed health care services.
AbbVie didn’t get everything it sought from a citizen petition but may still have the upper hand over smaller rivals after FDA gives makers of animal-derived thyroid medications a year to seek approval. If the agency removes compounded products, it could face more pricing pushback.
The findings are consistent with some other research and likely are due to obesity patients becoming more connected to needed health care services.
Chiesi’s orphan drug Raxone has secured an English funding recommendation for the treatment of Leber's hereditary optic neuropathy, a decade after the orphan drug was approved for marketing. Chiesi told the Pink Sheet about its “long, and often challenging” road to reimbursement.
